

University of Dundee

The extracellular matrix and insulin resistance

Williams, Ashley S.; Kang, Li; Wasserman, David H.

Published in:
Trends in Endocrinology and Metabolism

DOI:
[10.1016/j.tem.2015.05.006](https://doi.org/10.1016/j.tem.2015.05.006)

Publication date:
2015

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Williams, A. S., Kang, L., & Wasserman, D. H. (2015). The extracellular matrix and insulin resistance. *Trends in Endocrinology and Metabolism*, 26(7), 357-366. <https://doi.org/10.1016/j.tem.2015.05.006>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Trends in Endocrinology and Metabolism

The Extracellular Matrix and Insulin Resistance

--Manuscript Draft--

Manuscript Number:	TEM-D-15-00054R1
Article Type:	Review
Corresponding Author:	David Wasserman, Ph.D. Vanderbilt University Nashville, TN UNITED STATES
First Author:	Ashley Silberman Williams, Ph.D.
Order of Authors:	Ashley Silberman Williams, Ph.D.
	Li Kang, Ph.D.
	David H Wasserman, Ph.D.
Abstract:	<p>The extracellular matrix (ECM) is a highly dynamic compartment that undergoes remodeling as a result of injury and repair. Over the past decade, mounting evidence in humans and rodents suggest that ECM remodeling is associated with diet-induced insulin resistance in several metabolic tissues. Additionally, integrin receptors for the ECM have also been implicated in the regulation of insulin action. This review will address what is currently known about the ECM, integrins and insulin action in the muscle, liver and adipose tissue. Understanding how ECM remodeling and integrin signaling regulates insulin action may aid in the development of new therapeutic targets for the treatment of insulin resistance and type 2 diabetes.</p>

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The Extracellular Matrix and Insulin Resistance

Ashley S. Williams¹, Li Kang² and David H. Wasserman^{1,3}

From the ¹Department of Molecular Physiology and Biophysics, Vanderbilt University,
Nashville, TN, USA ²Division of Cardiovascular and Diabetes Medicine, Ninewells Hospital and
Medical School, University of Dundee, Dundee, UK ³Mouse Metabolic Phenotyping Center,
Vanderbilt University, Nashville, TN, USA

Corresponding author: Wasserman, D.H. (david.wasserman@vanderbilt.edu)

Keywords: Extracellular matrix, integrins, glucose homeostasis, insulin resistance, liver, muscle

Abstract:

The extracellular matrix (ECM) is a highly dynamic compartment that undergoes remodeling as a result of injury and repair. Over the past decade, mounting evidence in humans and rodents suggest that ECM remodeling is associated with diet-induced insulin resistance in several metabolic tissues. Additionally, integrin receptors for the ECM have also been implicated in the regulation of insulin action. This review will address what is currently known about the ECM, integrins and insulin action in the muscle, liver and adipose tissue. Understanding how ECM remodeling and integrin signaling regulates insulin action may aid in the development of new therapeutic targets for the treatment of insulin resistance and type 2 diabetes.

Overview of the extracellular matrix and integrins

The extracellular matrix (ECM) (Glossary) is composed of a diverse network of proteins and proteoglycans [1]. It provides a scaffold for cells and modulates biological processes including differentiation, cell migration, repair and development [2, 3]. The interaction between cells and the ECM is important for all organs. The ECM communicates with cells through transmembrane cell surface receptors called integrins [4]. Integrins bind the ECM and transduce signals through the plasma membrane to activate intracellular signaling. Integrins themselves lack kinase activity. Thus, they are reliant on scaffolding proteins and downstream kinases for signal transduction. Integrins signal through various proteins including focal adhesion kinase (FAK) and integrin-linked kinase (ILK) (**Box 1**). The detailed structure and function of integrins have been reviewed elsewhere [1, 4, 5].

The ECM is a dynamic structure that remodels during times of injury and repair [6]. Pathological states are associated with ECM remodeling and alterations in integrin expression. In obese conditions, the expression of ECM proteins increases several-fold, while a shift appears to occur from low-density ECM proteins to more fibril-forming proteins. Several recent lines of evidence suggest that ECM remodeling and changes in integrin signaling in the diet-induced obese (DIO) state are associated with insulin resistance [7-16]. The potential mechanisms whereby this occurs are represented in **Figure 1**. Herein we discuss recent findings related to the emerging link between ECM remodeling, integrin signaling and insulin resistance in the skeletal muscle, liver, and adipose tissue.

The Skeletal Muscle

Mechanisms of High Fat Diet-induced ECM Remodeling in the Skeletal Muscle

Inflammation and elevated transforming growth factor (TGF) β signaling are associated with muscle ECM remodeling, in obese mice and humans [17]. Mice fed a high fat diet (HFD) exhibit increased infiltration of pro-inflammatory M1-activated (CD11c⁺) macrophages in muscle [18]. Additionally, CD68⁺ macrophages are elevated in obese individuals [19]. The association between ECM remodeling and inflammation was further shown in a study by Kang et al. [9]. In this study, 20 weeks of HF feeding in mice led to increased muscle collagen content associated with increased gene expression of the pro-inflammatory marker tumor necrosis factor (TNF α) and the macrophage marker F4/80. Importantly, gene expression for these inflammatory markers was diminished in mouse models of improved insulin sensitivity and decreased muscle collagen deposition. It is possible that increased recruitment of pro-inflammatory macrophages may lead to ECM remodeling via TGF β -mediated Smad activation [20]. Smad3 activation is elevated in skeletal muscle biopsies of obese individuals compared to lean controls [17]. Collectively, this suggests that ECM remodeling in obese skeletal muscle occurs as a result of increased inflammation.

The Skeletal Muscle ECM and Glucose Metabolism

Insulin resistant muscle in obese and type 2 diabetic (T2D) humans is characterized by increased collagen deposition [7, 8]. Rapid weight gain in healthy young males resulted in impaired insulin sensitivity and the up-regulation of several muscle ECM genes [21]. There was no evidence of local adipose tissue or systemic inflammation despite weight gain, suggesting a key role for muscle ECM in the regulation of glucose homeostasis rather than secondary effects due to adipose tissue

inflammation.

Muscle collagen content is also increased in DIO, insulin resistant mice [9]. Studies by Kang et al. showed that increased collagen deposition in the DIO state is due to in part to decreased muscle matrix metalloproteinase 9 (MMP9) activity [9], and that the genetic deletion of MMP9 in mice increases collagen deposition in the muscle and exacerbates muscle insulin resistance in HF-fed mice [15].

Hyaluronan is an anionic, nonsulfated glycosaminoglycan. As a major component of the ECM, hyaluronan has multiple functions, including creating space between cells [22]. Serum hyaluronan is increased in T2D [23]. Insulin resistant animals have increased hyaluronan in muscles [16], aorta [24], and kidneys [25]. Elevated muscle hyaluronan levels are associated with muscle insulin resistance in the obese state. A reduction of muscle hyaluronan by intravenous injection of pegylated human recombinant hyaluronidase PH-20 (PEGPH20) results in a dose-dependent increase in glucose infusion rate and muscle glucose uptake during a hyperinsulinemic-euglycemic clamp [16]. This study showed for the first time that whole-body depletion of an ECM polysaccharide rescues insulin sensitivity in C57BL/6J HF-fed mice.

There are several hypotheses as to how increased muscle ECM in the HF-fed state contributes to insulin resistance, which may co-exist. A first hypothesis, the ECM is a physical barrier to both glucose and insulin diffusion. Proteins buildup in the interstitial space and this impedes substrate delivery to the muscle by increasing diffusion distance. A second hypothesis is that increases in muscle ECM impair neo-vascular growth and vascular function. The ECM is in close contact with

the endothelium. Blood flow and capillary recruitment are critical for proper glucose and insulin delivery to the muscle. Vascular dysfunction and capillary rarefaction (reduced capillary density) have long been implicated in the development of muscle insulin resistance and T2D [26]. Reduced blood flow to the muscle is correlated with insulin resistance, and conversely, the number of muscle capillaries is positively related to peripheral insulin action [27, 28]. Additionally, three weeks of treatment with the hormone relaxin, improved muscle insulin action through effects on the vasculature [29]. Kang and colleagues have provided consistent evidence that increased muscle capillaries are associated with improved muscle insulin action in HF-fed mice [9, 15]. This was evident in several mouse models, including the muscle-specific mitochondrial targeted catalase transgenic mice [9], chronic sildenafil-treated mice [9] and hyaluronidase-treated mice [16]. In contrast, decreased muscle capillaries are associated with exacerbated muscle insulin resistance in the global MMP9 knockout mouse [15]. It is important to consider that the first and second hypotheses are inextricably linked, as a decrease in capillarity will increase spatial barriers and diffusion distance for hormones and nutrients. Collectively, these data strongly suggest endothelial dysfunction and muscle capillary rarefaction are potential mechanisms by which ECM remodeling mediates muscle insulin resistance. Finally, the ECM may signal directly through muscle integrins to modulate insulin action (Figure 2). This is discussed in detail below.

Integrins and Skeletal Muscle Insulin Resistance

Skeletal muscle expresses seven integrin α subunits ($\alpha 1$, $\alpha 3$, $\alpha 4$, $\alpha 5$, $\alpha 6$, $\alpha 7$, and αv), and are all associated with the $\beta 1$ integrin subunit [30]. Remarkably, few studies have addressed the role of integrin signaling in the muscle with respect to muscle insulin resistance *in vivo*. The muscle-specific deletion of integrin $\beta 1$ in chow-fed mice results in decreased whole-body insulin

sensitivity, and decreased insulin-stimulated muscle glucose uptake during a hyperinsulinemic-euglycemic clamp [31]. Notably, the loss of skeletal muscle $\beta 1$ has no effect on liver or adipose tissue glucose metabolism. The decrease in insulin-stimulated muscle glucose uptake was associated with decreased muscle glycogen synthesis and decreased Akt S473 phosphorylation. Moreover, the whole-body deletion of integrin $\alpha 2$ in obese, HF-fed mice, partially reverses diet-induced muscle insulin resistance, as evidenced by increased insulin-stimulated muscle glucose uptake during a hyperinsulinemic-euglycemic clamp, and increased insulin signaling [9] (Figure 3). These data suggest that integrin signaling might be a mechanistic link between the muscle ECM and insulin resistance.

The downstream integrin signaling molecule, FAK, has been implicated in the regulation of insulin action in the muscle [32-34]. FAK tyrosine phosphorylation is decreased in muscle from HF-fed rats [32]. The *in vivo* siRNA-mediated knockdown of FAK results in hyperglycemia, hyperinsulinemia, impaired glucose tolerance and decreased insulin action in chow-fed mice [34]. The overexpression of FAK in C2C12 mouse myoblasts increases insulin-stimulated glucose uptake [35]. Conversely, C2C12 cells transfected with siRNA against FAK exhibit decreased insulin-stimulated glucose uptake [32]. L6 myocytes transfected with antisense FAK display decreased insulin signaling associated with decreased insulin-stimulated glucose uptake, decreased glycogen synthesis and impaired Glut4 translocation [33]. Collectively, these studies suggest that integrins mediate muscle glucose metabolism via their effects on both vascularization and glucose transport through Glut4.

No information exists about the role of ILK in the regulation of muscle glucose homeostasis. Mice with a muscle-specific deletion of ILK have been generated and are viable [36]. Considering the interaction of ILK with several known insulin signaling molecules such as Akt and GSK-3 β , it is highly possible that ILK modulates muscle insulin action. Future studies should be designed to determine whether ILK regulates muscle insulin action in the DIO mouse model.

ECM remodeling and mechano-signal transduction

ECM remodeling is also reflected by alterations in mechano-signal transduction to the nucleus and mitochondria [37, 38]. This may be a consequence of disturbances in actin and intermediate filament organization and/or the sarcoglycan complex, a junction whereby the myofiber interacts with the ECM. The sarcoglycan complex is critical for both force and mechano-signal transduction to the nucleus and mitochondrion. Disturbances in this complex produce metabolic effects [39]. Mice lacking the sarcoglycan complex in the muscle and adipose tissue demonstrate whole body insulin resistance attributed to impaired insulin-stimulated muscle glucose uptake [39]. Additionally, changes in the ECM of insulin resistant human muscle are accompanied by decreased abundance of the key filament organizational proteins, actinin 2 and desmin. It is plausible that these alterations may impair the ability of the muscle to adapt to exercise via compromised mechano-signal transduction to the nucleus or mitochondria that, under normal conditions, would induce gene transcription in response to exercise. In support of the ECM modulating mitochondrial function in the skeletal muscle, there is evidence that alterations in the collagen VI composition of the matrix affect mitochondrial function [37, 38]. Insulin resistant muscle is characterized by alterations in exercise tolerance and mitochondrial function, thus this provides another route whereby the ECM may regulate muscle insulin action.

The Liver

Mechanisms of HFD-induced ECM Remodeling in the Liver

The liver ECM expands with over-nutrition. Mice fed a HFD display increased hepatic staining for α -smooth muscle actin (SMA, a marker of stellate cell activation) and collagen, as well as increased collagen type I $\alpha 1$ gene expression [11]. Mice fed a HFD with high fructose water exhibit increased hepatic collagen type I $\alpha 1$ gene expression [10]. Moreover, Williams et al. recently demonstrated that mice fed a 60% HFD exhibit increased gene expression for collagen types I and III [12].

The specific process whereby ECM remodeling in the liver occurs in the presence of over-nutrition is undefined. However, one prevailing hypothesis is a “two hit” hypothesis [40]. The “first hit” is the accumulation of lipid metabolites. This leads to a series of events including lipotoxicity, oxidative stress, and inflammation that produce a “second hit”. The “second hit” promotes tissue injury and the activation of stellate cells. This process is initiated by autocrine and paracrine stimuli including inflammatory cytokines and growth factors such as TGF β [41-43]. Increased TGF β signaling is associated with hepatic collagen synthesis [44]. Once activated, stellate cells deposit ECM proteins in the space of Disse as part of a wound healing response, resulting in changes in the ECM and fibrosis [45]. Although it has been widely proposed that stellate cells are the main contributor to ECM deposition in the liver, it is possible that other cell types are involved [46]. The notion that stellate cells are the main contributor was based on *in vitro* studies performed in cell culture [47, 48]. However, several cell types in the intact liver are capable of ECM synthesis, including hepatocytes, endothelial cells, as well as stellate cells [2]. Considering that hepatocytes

comprise approximately 80% of the liver [49], it is feasible that they contribute to the hepatic ECM.

The Liver ECM and Glucose Metabolism

T2D in humans is associated with hepatic ECM remodeling [50, 51]. Patients with T2D exhibit increased staining for collagen type IV, α -SMA and a tendency for increased laminin staining [50]. In a separate study, liver biopsies from diabetic patients showed increased perisinusoidal fibrosis, characterized by immunostaining for laminin in sinusoidal spaces, as well as collagen type IV and α -SMA in the space of Disse [51]. It is important to note that early markers of ECM remodeling occur in diabetic patients prior to more advanced fibrosis and cirrhosis.

It is evident that a diet high in fat is associated with insulin resistance and ECM remodeling in the liver. Bonner et al. [29] showed that three weeks of relaxin treatment in HF-fed mice, results in decreased hepatic collagen type III, and a subsequent improvement in hepatic insulin action. In light of this, it is important to note that only one study to date has demonstrated a causal link between ECM remodeling and insulin resistance [16]. Kang et al. showed that depletion of systemic hyaluronan via tail vein injection of a long-acting hyaluronidase reverses HFD-induced liver insulin resistance [16].

CD44, the main hyaluronan cell surface receptor, is associated with T2D, as shown by expression-based genome-wide association studies (GWAS) [52]. CD44 is ubiquitously expressed, and its expression level in liver is positively correlated with hepatic steatosis and insulin resistance, in obese humans and DIO mice [52, 53]. Kodama et al. reported that anti-CD44 antibody treatment

lowers glycemia, improves insulin sensitivity and hepatic steatosis in DIO mice [54]. It is important to note that CD44 can also interact with other ligands, such as osteopontin, collagens and MMPs. Therefore, it is unclear whether the phenotype of mice lacking functional CD44 is due to prevention of hyaluronan or osteopontin or both. Hence, the role of CD44 signaling in diet-induced insulin resistance remains unclear, and warrants future investigation. Collectively, these studies highlight the role of the liver ECM in the regulation of glucose homeostasis.

There are two existing hypotheses as to how the hepatic ECM contributes to changes in insulin action. The first is through cellular and microcirculatory changes as a result of diet-induced ECM remodeling. In the liver, it is reasonable to speculate that diet-induced ECM remodeling (i.e. sinusoidal capillarization) sensitizes the liver to further damage and may facilitate maladaptive changes in hepatic insulin action [55]. The liver is a major site of insulin clearance. It is estimated that 50% of insulin is extracted by the liver during the first pass, via a receptor-mediated process [56-58]. Hepatic insulin extraction from the circulation reflects the ability of the liver to adequately respond to an insulin stimulus. Patients with cirrhosis and chronic hepatitis display decreased hepatic insulin extraction, compared to normal subjects [59]. This decrease in insulin clearance can be attributed to either liver damage or shunting of the portal-systemic circulation [59]. An extension of this is impaired insulin action and ultimately insulin resistance. A second hypothesis is that, as in muscle, the ECM signals through integrins and this regulates insulin action.

Integrins and Liver Insulin Resistance

Six α integrin subunits ($\alpha 1$, $\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 5$ and $\alpha 6$) are expressed in the liver, all of which are associated with the $\beta 1$ integrin [60]. Of these six α subunits, only two integrins have been shown

to be expressed on the hepatocyte: integrin $\alpha 1\beta 1$ and $\alpha 5\beta 1$. Integrin $\alpha 5\beta 1$ is a fibronectin receptor, and integrin $\alpha 1\beta 1$ is a collagen binding integrin. The genetic whole body deletion of the integrin $\alpha 1$ subunit in mice exists and is viable [61]. Studies show that integrin $\alpha 1\beta 1$ protects against the development of hepatic insulin resistance [9, 12] (Figure 4). Williams et al. demonstrated that integrin $\alpha 1$ protein expression is upregulated in hepatocytes isolated from HF-fed mice, compared to chow-fed controls [12]. Thus, to determine whether this response protected against hepatic metabolic impairments in DIO mice, insulin sensitivity was determined in integrin $\alpha 1$ -null mice and their wild-type littermates. This study showed that deletion of the integrin $\alpha 1$ subunit results in severe hepatic insulin resistance in HF-fed mice and decreased hepatic insulin signaling. It is currently unknown whether some unidentified integrin $\alpha 1$ subunit binding protein is modulating the observed protective effect. Moreover, the role of integrin $\alpha 5\beta 1$ in hepatic insulin action *in vivo* has not been investigated. It is possible, in the integrin $\alpha 1$ subunit null mice, that the severe hepatic insulin resistance is attributable to enhanced integrin $\alpha 5\beta 1$ signaling. Future studies should be conducted to identify novel integrin $\alpha 1$ subunit binding partners and/or to determine whether integrin $\alpha 5\beta 1$ contributes to or protects against diet-induced hepatic insulin resistance.

FAK has been heavily implicated in the regulation of glucose homeostasis and insulin action in the liver [33, 34, 62]. FAK undergoes rapid tyrosine phosphorylation in livers from healthy rats upon insulin stimulation under euglycemic conditions *in vivo* [62]. This is consistent with a separate study showing that HepG2 cells transfected with mutant FAK constructs display decreased Akt Ser473 and GSK-3 Ser9 phosphorylation [63]. There was no difference in the insulin receptor phosphorylation or PI3K activity, upon insulin stimulation suggesting that FAK exerts its actions on insulin signaling downstream of the insulin receptor [64]. FAK tyrosine

phosphorylation is decreased in HF-fed mice [12]. The *in vivo* siRNA-mediated knockdown of FAK results in hyperglycemia, hyperinsulinemia, and impaired glucose tolerance in chow-fed mice [34]. Finally, *fa/fa* rats treated with a TNF- α neutralizing agent exhibited increased hepatic FAK phosphorylation associated with decreased hepatic glucose output during an insulin clamp [62, 65]. These studies suggest that decreased integrin signaling through FAK may facilitate the development of hepatic insulin resistance.

Little is known about the role of integrin-linked kinase (ILK) in the regulation of hepatic insulin action. However, several studies suggest that ILK modulates the activation of several key insulin signaling proteins, including Akt and GSK-3 β [66-68]. The stimulation of hepatic stellate cells in rats using carbon tetrachloride (CCl₄) resulted in increased ILK protein expression, associated with enhanced phosphorylation of Akt, while the inhibition of ILK by siRNA prevented this [66]. In contrast, the phosphorylation of Akt Ser473 is not affected in mice with a hepatocyte-specific deletion of ILK [67], and ILK-deficient cells are capable of phosphorylating Akt at both Thr308 and Ser473 upon insulin stimulation, similar to control cells [68]. Thus, the role of ILK in the regulation of Akt and GSK-3 phosphorylation is currently unresolved and more studies are necessary to address whether ILK mediates insulin signaling *in vivo*. The regulation of hepatic insulin action by integrins is multifaceted, and more studies are necessary to determine the actions of each integrin and integrin signaling molecule on hepatic insulin action, to aid in the determination of future therapeutics.

The Adipose Tissue

Mechanisms of High Fat Diet-induced ECM Remodeling in Adipose Tissue

The adipose tissue responds dynamically to nutrient excess through adipocyte hypertrophy and hyperplasia [69]. This is followed by increased production of pro-inflammatory adipokines, immune cell infiltration and ECM remodeling. Excessive collagen deposition has been observed in the adipose tissue of various models of overnutrition [13, 70, 71]. Collagen VI is a highly enriched ECM protein in adipose tissue and its expression is increased in obese humans [70]. Additionally, collagen gene expression (types I, III, V, and VI) is increased in adipose tissue from obese leptin receptor deficient *db/db* mice, and this is further exacerbated when the mice are fed a HFD [13]. Collectively, this suggests that ECM remodeling is a characteristic of obese adipose tissue.

Hypoxia and inflammation are stimuli for ECM remodeling during adipose tissue expansion. HF feeding in rodents leads to the doubling of fat cell area accompanied by local hypoxia [72]. Hypoxia in obese adipose tissue occurs as the local vasculature fails to expand appropriately to meet the demands of increased fat mass. In support of this, gene expression of vascular endothelial growth factor (VEGF)-A and vessel density are decreased in the adipose tissue of *ob/ob* mice [72]. Hypoxia then leads to HIF1 α activation and the secretion of pro-inflammatory cytokines from adipocytes [72, 73]. The combination of hypoxia and inflammation culminates in the pathological expansion of adipose ECM as adipocytes and recruited macrophages express and secrete collagens [70, 71, 74]. The mechanisms underlying ECM remodeling in adipose tissue have been reviewed in detail elsewhere [69, 75].

The Adipose Tissue ECM and Glucose Metabolism

One hallmark of metabolically dysfunctional adipose tissue is the pathological accumulation of ECM proteins. Increased collagen deposition is a physical barrier for adipocyte expansion during the development of obesity and this promotes the shunting of lipids into other tissues. A role for collagen in the obese, metabolically impaired adipose tissue was recently established [71]. The deletion of collagen VI in *ob/ob* mice results in un-impeded adipocyte expansion, improved glucose tolerance and insulin signaling. Additionally, the overexpression of the $\alpha 3$ chain of collagen VI (endotrophin) in mice stimulates deposition of other collagen types, mainly collagen I, III and VI and insulin resistance in the presence of a HFD [76].

Thrombospondin 1 (THBS1) is a large adhesive ECM glycoprotein expressed predominantly in visceral adipose tissue and its expression is elevated in insulin-resistant, obese humans [19]. In mice, HF feeding acutely induces adipose tissue *Thbs1* expression and increases circulating THBS1 levels [14]. Genetic deletion of *Thbs1* in mice protects against HFD induced adipose tissue inflammation and insulin resistance [14]. Circulating THBS1 may also induce fibrosis in skeletal muscle and induce insulin resistance [14]. This is evident as *Thbs1*-null skeletal muscle are protected from HFD-induced collagen deposition and insulin resistance. Moreover, expression of the pro-inflammatory ECM glycoprotein, tenascin C, is also upregulated in the adipose tissue of obese mice and humans [77] and may contribute to insulin resistance.

The composition of ECM reflects a balance between matrix synthesis and degradation. Adipose tissue remodeling is altered in the obese state by ECM proteolysis via the fibrinolytic systems and matrix metalloproteinases (MMPs) [69]. MMPs are a family of zinc dependent proteinases

responsible for the degradation of ECM proteins [78]. MMP dysregulation has been implicated in the pathophysiology of obesity and diabetes. Plasma MMP2 and MMP9 concentrations are increased in obese [79] and diabetic [80, 81] individuals. Additionally, gene expression of adipose MMP9 correlates positively with altered HOMA-IR index in morbidly obese individuals [82].

MMPs are regulated by tissue inhibitors of metalloproteinases (TIMPs), which comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4 [83]. Circulating TIMP-1 and TIMP-2 are increased in patients with metabolic syndrome and diabetes [81]. Overexpression of TIMP1 in pancreatic β -cells protects mice from streptozotocin-induced β -cell death and diabetes [84]. Likewise, genetic deletion of TIMP2 results in obesity and glucose intolerance in chow-fed mice that is further exacerbated in HF-fed mice [85]. TIMP3 is reduced in the adipose tissue of experimental models of obesity and insulin resistance [86]. Genetic deletion of TIMP3 in mice promotes adipose tissue inflammation [87] and TIMP3 overexpression in macrophages protects against adipose tissue inflammation and insulin resistance [88]. These data suggest that increased tissue TIMPs are protective from insulin resistance. This is paradoxical as TIMPs inhibit MMP activities. Thus in-depth investigations into the role of MMPs and TIMPs in obesity and insulin resistance should be a fruitful future direction for research.

Concluding remarks and future perspectives

The regulation of insulin action in the DIO state is complex. Many questions remain as to how metabolic disease develops and persists over time. The ECM and integrins are emerging as critical regulators of insulin action in the muscle, liver and adipose tissue. Until recently, few studies had addressed the contribution of the extracellular compartment to the regulation of glucose

metabolism. The observation that ECM remodeling occurs in both human and rodent models of insulin resistance and T2D was a great step forward in understanding this previously uncharacterized portion of insulin sensitive tissues. ECM remodeling in the obese state has been attributed to increased inflammation and the subsequent up regulation of pro-fibrotic signaling molecules including TGF β . It is currently unknown how the ECM regulates insulin action; however several hypotheses exist to explain this phenomenon. First, ECM remodeling generates a mechanical barrier for (a) glucose and insulin transport in the muscle and liver and (b) adipocyte hypertrophy in the adipose tissue under conditions of overnutrition. Second, changes in the composition of the ECM results in downstream alterations in integrin signaling that culminate in impaired insulin action. In light of these hypotheses, several important outstanding questions endure (**Box 2**). Future studies that seek to determine the mechanisms underlying diet-induced ECM remodeling and the mechanistic link between ECM remodeling, integrin signaling and insulin action in metabolic tissues are vital to advancing this great new line of investigation. In conclusion, the ECM and integrins are important regulators of insulin action and represent novel therapeutic targets to treat the underlying insulin resistance associated with T2D.

Acknowledgments

This work was supported by National Institutes of Health Grants DK54902 (DHW), DK050277 (DHW) and DK059637 (DHW).

References

1. Hynes, R.O. (2009) The extracellular matrix: not just pretty fibrils. *Science* 326, 1216-1219.
2. Martinez-Hernandez, A., *et al.* (1995) The extracellular matrix in hepatic regeneration. *FASEB J.* 9, 1401-1410.
3. Schuppan, D. (1990) Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. *Semin. Liver Dis.* 10, 1-10.
4. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. *Cell* 110, 673-687.
5. Moser, M., *et al.* (2009) The tail of integrins, talin, and kindlins. *Science* 324, 895-899.
6. Pozzi, A., *et al.* (2003) Integrins: sensors of extracellular matrix and modulators of cell function. *Nephron. Experimental nephrology* 94, e77-84.
7. Richardson, D.K., *et al.* (2005) Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. *J. Biol. Chem.* 280, 10290-10297.
8. Berria, R., *et al.* (2006) Increased collagen content in insulin-resistant skeletal muscle. *American journal of physiology. Endocrinology and metabolism* 290, E560-565.
9. Kang, L., *et al.* (2011) Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin $\alpha 2 \beta 1$ in mice. *Diabetes* 60, 416-426.
10. Wada, T., *et al.* (2013) Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. *American journal of physiology. Endocrinology and metabolism* 305, E1415-1425.

- 401 11. Dixon, L.J., *et al.* (2013) Caspase-1 as a central regulator of high fat diet-induced non-
402 alcoholic steatohepatitis. *PloS one* 8, e56100.
- 403 12. Williams, A.S., *et al.* (2015) Integrin alpha1-null Mice Exhibit Improved Fatty Liver When
404 Fed a High Fat Diet Despite Severe Hepatic Insulin Resistance. *J. Biol. Chem.*
- 405 13. Huber, J., *et al.* (2007) Prevention of high-fat diet-induced adipose tissue remodeling in
406 obese diabetic mice by n-3 polyunsaturated fatty acids. *Int J Obes (Lond)* 31, 1004-1013.
- 407 14. Inoue, M., *et al.* (2013) Thrombospondin 1 mediates high-fat diet-induced muscle fibrosis
408 and insulin resistance in male mice. *Endocrinology* 154, 4548-4559.
- 409 15. Kang, L., *et al.* (2014) Matrix metalloproteinase 9 opposes diet-induced muscle insulin
410 resistance in mice. *Diab tologia* 57, 603-613.
- 411 16. Kang, L., *et al.* (2013) Hyaluronan accumulates with high-fat feeding and contributes to
412 insulin resistance. *Diabetes* 62, 1888-1896.
- 413 17. Watts, R., *et al.* (2013) Increased Smad signaling and reduced MRF expression in skeletal
414 muscle from obese subjects. *Obesity (Silver Spring)* 21, 525-528.
- 415 18. Hong, E.G., *et al.* (2009) Interleukin-10 prevents diet-induced insulin resistance by
416 attenuating macrophage and cytokine response in skeletal muscle. *Diabetes* 58, 2525-2535.
- 417 19. Varma, V., *et al.* (2009) Muscle inflammatory response and insulin resistance: synergistic
418 interaction between macrophages and fatty acids leads to impaired insulin action. *American*
419 *journal of physiology. Endocrinology and metabolism* 296, E1300-1310.
- 420 20. Yadav, H., *et al.* (2011) Protection from obesity and diabetes by blockade of TGF-
421 beta/Smad3 signaling. *Cell metabolism* 14, 67-79.
- 422 21. Tam, C.S., *et al.* (2014) Weight gain reveals dramatic increases in skeletal muscle
423 extracellular matrix remodeling. *J. Clin. Endocrinol. Metab.* 99, 1749-1757.

- 424 22. Toole, B.P. (2004) Hyaluronan: from extracellular glue to pericellular cue. *Nature reviews.*
425 *Cancer* 4, 528-539.
- 426 23. Dasu, M.R., *et al.* (2010) Increased toll-like receptor (TLR) activation and TLR ligands in
427 recently diagnosed type 2 diabetic subjects. *Diabetes Care* 33, 861-868.
- 428 24. Chajara, A., *et al.* (2000) Increased hyaluronan and hyaluronidase production and
429 hyaluronan degradation in injured aorta of insulin-resistant rats. *Arterioscler. Thromb.*
430 *Vasc. Biol.* 20, 1480-1487.
- 431 25. Lewis, A., *et al.* (2008) Diabetic nephropathy, inflammation, hyaluronan and interstitial
432 fibrosis. *Histol. Histopathol.* 23, 731-739.
- 433 26. Jansson, P.A. (2007) Endothelial dysfunction in insulin resistance and type 2 diabetes. *J.*
434 *Intern. Med.* 262, 173-183.
- 435 27. Solomon, T.P., *et al.* (2011) Progressive hyperglycemia across the glucose tolerance
436 continuum in older obese adults is related to skeletal muscle capillarization and nitric oxide
437 bioavailability. *J. Clin. Endocrinol. Metab.* 96, 1377-1384.
- 438 28. Bonner, J.S., *et al.* (2013) Muscle-specific vascular endothelial growth factor deletion
439 induces muscle capillary rarefaction creating muscle insulin resistance. *Diabetes* 62, 572-
440 580.
- 441 29. Bonner, J.S., *et al.* (2013) Relaxin treatment reverses insulin resistance in mice fed a high-
442 fat diet. *Diabetes* 62, 3251-3260.
- 443 30. Gullberg, D., *et al.* (1998) Integrins during muscle development and in muscular
444 dystrophies. *Front. Biosci.* 3, D1039-1050.
- 445 31. Zong, H., *et al.* (2009) Insulin resistance in striated muscle-specific integrin receptor beta1-
446 deficient mice. *J. Biol. Chem.* 284, 4679-4688.

- 447 32. Bisht, B., *et al.* (2007) Focal adhesion kinase regulates insulin resistance in skeletal muscle.
448 *Diabetes* 50, 1058-1069.
- 449 33. Huang, D., *et al.* (2006) Reduced expression of focal adhesion kinase disrupts insulin
450 action in skeletal muscle cells. *Endocrinology* 147, 3333-3343.
- 451 34. Bisht, B., *et al.* (2008) In vivo inhibition of focal adhesion kinase causes insulin resistance.
452 *The Journal of physiology* 586, 3825-3837.
- 453 35. Bisht, B., *et al.* (2008) Focal Adhesion Kinase contributes to insulin-induced actin
454 reorganization into a mesh harboring Glucose transporter-4 in insulin resistant skeletal
455 muscle cells. *BMC cell biology* 9, 48.
- 456 36. Gheyara, A.L., *et al.* (2007) Deletion of integrin-linked kinase from skeletal muscles of
457 mice resembles muscular dystrophy due to alpha 7 beta 1-integrin deficiency. *Am. J.*
458 *Pathol.* 171, 1966-1977.
- 459 37. Zamurs, L.K., *et al.* (2015) Aberrant mitochondria in a Bethlem myopathy patient with a
460 homozygous amino acid substitution that destabilizes the collagen VI alpha2(VI) chain. *J.*
461 *Biol. Chem.* 290, 4272-4281.
- 462 38. Irwin, W.A., *et al.* (2003) Mitochondrial dysfunction and apoptosis in myopathic mice with
463 collagen VI deficiency. *Nat. Genet.* 35, 367-371.
- 464 39. Groh, S., *et al.* (2009) Sarcoglycan complex: implications for metabolic defects in
465 muscular dystrophies. *J. Biol. Chem.* 284, 19178-19182.
- 466 40. Day, C.P., *et al.* (1998) Steatohepatitis: a tale of two "hits"? *Gastroenterology* 114, 842-
467 845.
- 468 41. Friedman, S.L. (2000) Molecular regulation of hepatic fibrosis, an integrated cellular
469 response to tissue injury. *J. Biol. Chem.* 275, 2247-2250.

- 470 42. Gressner, O.A., *et al.* (2007) Differential effects of TGF-beta on connective tissue growth
471 factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. *J. Hepatol.* 47,
472 699-710.
- 473 43. Eng, F.J., *et al.* (2000) Fibrogenesis I. New insights into hepatic stellate cell activation: the
474 simple becomes complex. *American journal of physiology. Gastrointestinal and liver*
475 *physiology* 279, G7-G11.
- 476 44. Carmiel-Haggai, M., *et al.* (2005) A high-fat diet leads to the progression of non-alcoholic
477 fatty liver disease in obese rats. *FASEB J.* 19, 136-138.
- 478 45. McCuskey, R.S., *et al.* (2004) Hepatic microvascular dysfunction during evolution of
479 dietary steatohepatitis in mice. *Hepatology* 40, 386-393.
- 480 46. Bataller, R., *et al.* (2001) Hepatic stellate cells as a target for the treatment of liver fibrosis.
481 *Semin. Liver Dis.* 21, 437-451.
- 482 47. Friedman, S.L., *et al.* (1985) Hepatic lipocytes: the principal collagen-producing cells of
483 normal rat liver. *Proc. Natl. Acad. Sci. U. S. A.* 82, 8681-8685.
- 484 48. Maher, J.J., *et al.* (1988) Collagen measured in primary cultures of normal rat hepatocytes
485 derives from lipocytes within the monolayer. *J. Clin. Invest.* 82, 450-459.
- 486 49. Postic, C., *et al.* (2000) DNA excision in liver by an albumin-Cre transgene occurs
487 progressively with age. *Genesis* 26, 149-150.
- 488 50. Jaskiewicz, K., *et al.* (2008) Fibrogenesis in fatty liver associated with obesity and diabetes
489 mellitus type 2. *Dig. Dis. Sci.* 53, 785-788.
- 490 51. Harrison, S.A. (2006) Liver disease in patients with diabetes mellitus. *J. Clin.*
491 *Gastroenterol.* 40, 68-76.

- 492 52. Kodama, K., *et al.* (2012) Expression-based genome-wide association study links the
493 receptor CD44 in adipose tissue with type 2 diabetes. *Proc. Natl. Acad. Sci. U. S. A.* 109,
494 7049-7054.
- 495 53. Bertola, A., *et al.* (2009) Elevated expression of osteopontin may be related to adipose
496 tissue macrophage accumulation and liver steatosis in morbid obesity. *Diabetes* 58, 125-
497 133.
- 498 54. Kodama, K., *et al.* (2015) Anti-CD44 Antibody Treatment Lowers Hyperglycemia and
499 Improves Insulin Resistance, Adipose Inflammation, and Hepatic Steatosis in Diet-Induced
500 Obese Mice. *Diabetes* 64, 867-875.
- 501 55. Farrell, G.C., *et al.* (2008) Hepatic microcirculation in fatty liver disease. *Anat Rec*
502 *(Hoboken)* 291, 684-692.
- 503 56. Madison, L.L., *et al.* (1959) Evidence for a direct effect of insulin on hepatic glucose
504 output. *Metabolism*. 8, 469-471.
- 505 57. Duckworth, W.C., *et al.* (1998) Insulin degradation: progress and potential. *Endocr. Rev.*
506 19, 608-624.
- 507 58. Field, J.B. (1973) Extraction of insulin by liver. *Annu. Rev. Med.* 24, 309-314.
- 508 59. Duckworth, W.C., *et al.* (1981) Insulin degradation by hepatocytes in primary culture.
509 *Endocrinology* 108, 1142-1147.
- 510 60. Volpes, R., *et al.* (1991) Distribution of the VLA family of integrins in normal and
511 pathological human liver tissue. *Gastroenterology* 101, 200-206.
- 512 61. Gardner, H., *et al.* (1996) Deletion of integrin alpha 1 by homologous recombination
513 permits normal murine development but gives rise to a specific deficit in cell adhesion.
514 *Dev. Biol.* 175, 301-313.

- 515 62. Cheung, A.T., *et al.* (2000) Tumor necrosis factor-alpha induces hepatic insulin resistance
516 in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine
517 phosphatase with focal adhesion kinase. *Diabetes* 49, 810-819.
- 518 63. Huang, D., *et al.* (2002) Focal adhesion kinase (FAK) regulates insulin-stimulated
519 glycogen synthesis in hepatocytes. *J. Biol. Chem.* 277, 18151-18160.
- 520 64. El Annabi, S., *et al.* (2001) Focal adhesion kinase and Src mediate integrin regulation of
521 insulin receptor phosphorylation. *FEBS Lett.* 507, 247-252.
- 522 65. Cheung, A.T., *et al.* (1998) An in vivo model for elucidation of the mechanism of tumor
523 necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential
524 regulation of insulin signaling by TNF-alpha. *Endocrinology* 139, 4928-4935.
- 525 66. Zhang, Y., *et al.* (2006) Involvement of integrin-linked kinase in carbon tetrachloride-
526 induced hepatic fibrosis in rats. *Hepatology* 44, 612-622.
- 527 67. Gkretsi, V., *et al.* (2007) Loss of integrin linked kinase from mouse hepatocytes in vitro
528 and in vivo results in apoptosis and hepatitis. *Hepatology* 45, 1025-1034.
- 529 68. Sakai, T., *et al.* (2003) Integrin-linked kinase (ILK) is required for polarizing the epiblast,
530 cell adhesion, and controlling actin accumulation. *Genes Dev.* 17, 926-940.
- 531 69. Catalan, V., *et al.* (2012) Role of extracellular matrix remodelling in adipose tissue
532 pathophysiology: relevance in the development of obesity. *Histol. Histopathol.* 27, 1515-
533 1528.
- 534 70. Pasarica, M., *et al.* (2009) Adipose tissue collagen VI in obesity. *J. Clin. Endocrinol.*
535 *Metab.* 94, 5155-5162.
- 536 71. Khan, T., *et al.* (2009) Metabolic dysregulation and adipose tissue fibrosis: role of collagen
537 VI. *Mol. Cell. Biol.* 29, 1575-1591.

- 538 72. Halberg, N., *et al.* (2009) Hypoxia-inducible factor 1alpha induces fibrosis and insulin
539 resistance in white adipose tissue. *Mol. Cell. Biol.* 29, 4467-4483.
- 540 73. Wang, B., *et al.* (2007) Dysregulation of the expression and secretion of inflammation-
541 related adipokines by hypoxia in human adipocytes. *Pflugers Arch.* 455, 479-492.
- 542 74. Keophipath, M., *et al.* (2009) Macrophage-secreted factors promote a profibrotic
543 phenotype in human preadipocytes. *Mol. Endocrinol.* 23, 11-24.
- 544 75. Sun, K., *et al.* (2013) Fibrosis and adipose tissue dysfunction. *Cell metabolism* 18, 470-
545 477.
- 546 76. Sun, K., *et al.* (2014) Endotrophin triggers adipose tissue fibrosis and metabolic
547 dysfunction. *Nature communications* 5, 3485.
- 548 77. Catalan, V., *et al.* (2012) Increased tenascin C and Toll-like receptor 4 levels in visceral
549 adipose tissue as a link between inflammation and extracellular matrix remodeling in
550 obesity. *J. Clin. Endocrinol. Metab.* 97, E1880-1889.
- 551 78. Thrailkill, K.M., *et al.* (2009) Matrix metalloproteinases: their potential role in the
552 pathogenesis of diabetic nephropathy. *Endocrine* 35, 1-10.
- 553 79. Derosa, G., *et al.* (2008) Matrix metalloproteinase-2 and -9 levels in obese patients.
554 *Endothelium* 15, 219-224.
- 555 80. Signorelli, S.S., *et al.* (2005) Plasma levels and zymographic activities of matrix
556 metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. *Vasc. Med.*
557 10, 1-6.
- 558 81. Hopps, E., *et al.* (2013) Gelatinases and their tissue inhibitors in a group of subjects with
559 metabolic syndrome. *J. Investig. Med.* 61, 978-983.

- 560 82. Tinahones, F.J., *et al.* (2012) Obesity-associated insulin resistance is correlated to adipose
561 tissue vascular endothelial growth factors and metalloproteinase levels. *BMC physiology*
562 12, 4.
- 563 83. Brew, K., *et al.* (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient
564 family with structural and functional diversity. *Biochim. Biophys. Acta* 1803, 55-71.
- 565 84. Jiang, H., *et al.* (2007) TIMP-1 transgenic mice recover from diabetes induced by multiple
566 low-dose streptozotocin. *Diabetes* 56, 49-56.
- 567 85. Jaworski, D.M., *et al.* (2011) Sexually dimorphic diet-induced insulin resistance in obese
568 tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice. *Endocrinology* 152, 1300-
569 1313.
- 570 86. Demeulemeester, D., *et al.* (2006) Overexpression of tissue inhibitor of matrix
571 metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue
572 development. *Thromb. Haemost.* 95, 1019-1024.
- 573 87. Menghini, R., *et al.* (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes
574 hepatic steatosis and adipose tissue inflammation in mice. *Gastroenterology* 136, 663-672
575 e664.
- 576 88. Menghini, R., *et al.* (2012) TIMP3 overexpression in macrophages protects from insulin
577 resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. *Diabetes*
578 61, 454-462.
- 579 89. Hanks, S.K., *et al.* (1992) Focal adhesion protein-tyrosine kinase phosphorylated in
580 response to cell attachment to fibronectin. *Proc. Natl. Acad. Sci. U. S. A.* 89, 8487-8491.

- 581 90. Plows, L.D., *et al.* (2006) Integrin engagement modulates the phosphorylation of focal
582 adhesion kinase, phagocytosis, and cell spreading in molluscan defence cells. *Biochim.*
583 *Biophys. Acta* 1763, 779-786.
- 584 91. Schlaepfer, D.D., *et al.* (1994) Integrin-mediated signal transduction linked to Ras pathway
585 by GRB2 binding to focal adhesion kinase. *Nature* 372, 786-791.
- 586 92. Ilic, D., *et al.* (1995) Reduced cell motility and enhanced focal adhesion contact formation
587 in cells from FAK-deficient mice. *Nature* 377, 539-544.
- 588 93. Delcommenne, M., *et al.* (1998) Phosphoinositide-3-OH kinase-dependent regulation of
589 glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. *Proc.*
590 *Natl. Acad. Sci. U. S. A.* 95, 11211-11216.
- 591 94. Troussard, A.A., *et al.* (2003) Conditional knock-out of integrin-linked kinase
592 demonstrates an essential role in protein kinase B/Akt activation. *J. Biol. Chem.* 278,
593 22374-22378.
- 594 95. Wang, H.V., *et al.* (2008) Integrin-linked kinase stabilizes myotendinous junctions and
595 protects muscle from stress-induced damage. *J. Cell Biol.* 180, 1037-1049.
- 596 96. White, D.E., *et al.* (2006) Targeted ablation of ILK from the murine heart results in dilated
597 cardiomyopathy and spontaneous heart failure. *Genes Dev.* 20, 2355-2360.
- 598 97. Vaynberg, J., *et al.* (2006) Weak protein-protein interactions as probed by NMR
599 spectroscopy. *Trends Biotechnol.* 24, 22-27.
- 600 98. Qian, F., *et al.* (2005) Interaction between integrin alpha(5) and fibronectin is required for
601 metastasis of B16F10 melanoma cells. *Biochem. Biophys. Res. Commun.* 333, 1269-1275.
- 602 99. Hill, M.M., *et al.* (2002) Identification of a plasma membrane Raft-associated PKB Ser473
603 kinase activity that is distinct from ILK and PDK1. *Curr. Biol.* 12, 1251-1255.

100. Persad, S., *et al.* (2001) Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. *J. Biol. Chem.* 276, 27462-27469.

Figure Legends

Figure 1: A link between extracellular matrix remodeling and insulin resistance.

A diet high in fat generates a state of chronic inflammation. This inflammatory response leads to increased ECM synthesis and decreased ECM degradation, resulting in increased deposition and remodeling of ECM. Increased levels of ECM lead to increased physical barriers for insulin and glucose transport, decreased vascular insulin delivery and decreased insulin signaling. The combination of all of these factors then culminates in insulin resistance.

Figure 2: The role of integrin $\alpha 2\beta 1$ diet-induced muscle insulin resistance.

In the HF-fed state, capillary density and endothelial function are impaired. This results in decreased potential for glucose and insulin transport into the interstitial space despite hyperglycemia and hyperinsulinemia. Moreover, increased ECM deposition in the interstitial space also provides a physical barrier to glucose and insulin transport to the myocyte. Insulin signaling within the myocyte is impaired and this may be attributed to increased integrin $\alpha 2\beta 1$ signaling as a consequence of increased deposition of the ECM. This results in impaired Glut4 translocation and decreased glucose transport into the myocyte. In contrast, the genetic deletion of the integrin $\alpha 2$ subunit results in improved insulin-stimulated muscle glucose uptake.

Figure 3: The role of integrin $\alpha 1\beta 1$ in diet-induced hepatic insulin resistance.

In the HF-fed state, sinusoidal capillarization occurs and this, in addition to increased ECM buildup in the space of Disse, results in decreased insulin transport to the hepatocyte despite hyperinsulinemia. Protein expression of the integrin $\alpha 1$ subunit is increased and this leads to increased $\alpha 1\beta 1$ cell signaling. Upon insulin stimulation, the combination of both insulin and integrin $\alpha 1\beta 1$ signaling results in some insulin signaling and the partial suppression of hepatic glucose output. In contrast, the genetic deletion of the integrin $\alpha 1$ subunit results in severe hepatic insulin resistance and no insulin-mediated suppression of hepatic glucose output. This is attributed to decreased insulin signaling. It is possible that this effect is mediated by integrin $\alpha 5\beta 1$, the only other known integrin expressed on the hepatocyte, however this is currently unknown.

Figure 4: Proposed model whereby integrins regulate insulin action.

In the presence of insulin, integrin signaling through both integrin linked kinase (ILK) and focal adhesion kinase (FAK) promotes insulin action. Canonical insulin signaling occurs, however it is possible that other mechanisms exist whereby insulin exerts its actions within the cell. Several studies show that FAK is an important regulator of insulin action in both the muscle and liver. Less is known about ILK. However, Nck2 is an adaptor protein shared by both the insulin receptor and ILK. This suggests that there may be a physical link between the insulin receptor and integrins through Nck2 and ILK, allowing the centralization of signaling through this complex. Akt, a critical insulin signaling molecule, is a known binding partner of ILK. Additionally, integrin signaling has been shown to modulate the assembly of the cytoskeleton and this may have effects on both mitochondrial function and insulin action.

Text Box 1: Integrin signaling molecules

Focal adhesion kinase

Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that localizes with integrin receptors at sites where cells attach to the ECM [89]. FAK undergoes rapid autophosphorylation at Tyr397 upon integrin-mediated cell adhesion [90], and this is associated with increased catalytic activity. Additionally, FAK can be regulated by the growth factor receptors epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR) and the insulin receptor [63, 91]. This results in the activation of several downstream signaling cascades including the MAPK and PI3K signaling pathways [63, 91]. In addition to its signaling properties, FAK is important for cytoskeletal stabilization and focal adhesion turnover [92].

Integrin-linked kinase and insulin action

Integrin-linked kinase (ILK) is a highly conserved intracellular scaffolding protein. It interacts with the $\beta 1$, $\beta 2$ and $\beta 3$ -integrin cytoplasmic domains and numerous cytoskeleton-associated proteins. It is composed of three distinct domains: an N-terminus that contains five ankyrin repeats, a pleckstrin homology-like domain and a pseudokinase domain at the C-terminus. Considering that it is a scaffolding protein, it has been proposed that ILK modulates intracellular signaling through its ability to recruit a kinase or multiple kinases into a multiprotein complex. This complex then facilitates the activation of downstream signaling molecules upon insulin stimulation. The pseudokinase domain of ILK is an essential domain for the recruitment of adaptor proteins and/or signaling molecules including several proteins involved in insulin action such as PKB/Akt, PDK1 and GSK-3 β . Overexpression of ILK or insulin treatment results in increased GSK-3 and Akt phosphorylation [93]. Co-transfection of Akt with wild-type ILK in 293 cells resulted in an enhancement of phosphorylation of Akt Ser473 [93]. Several studies have shown that the ablation

of ILK results in decreased Akt Ser473 phosphorylation [94-96]. Moreover, ILK is connected to growth factor receptors through the adaptor protein Nck2 [97]. Therefore, although ILK lacks intrinsic kinase activity, it has been shown to regulate the activation of numerous intracellular growth factor signaling cascades [98-100].

Box 2: Outstanding questions

- What role does inflammation have in diet-induced ECM remodeling? Which components of the inflammatory process are involved? Are the inflammatory stimuli acting locally or are they systemic?
- When does ECM remodeling occur during a time-course of HF feeding in rodent models? How does this relate to insulin action?
- Does ECM remodeling lead to insulin resistance by generating a physical barrier for glucose and insulin transport?
- How do integrins regulate insulin action *in vivo*? What components of the integrin signaling cascade are important for insulin action?

Glossary

Collagen: the most abundant structural protein consisting of three α polypeptide chains folded into a triple helix formation. Collagen proteins are divided into subgroups depending on their organization and/or molecular size that include the fibril forming collagens type I and III, the basement membrane associated collagen type IV and collagen type V, a minor ECM component.

Cirrhosis: late stage fibrosis of the liver as a result of different liver diseases and conditions such as hepatitis and chronic ethanol ingestion.

696 **Endothelial dysfunction:** deleterious alterations in endothelial physiology characterized by
697 impaired endothelium-dependent vasodilation due to decreased availability of vasodilators such as
698 NO and/or an increase in endothelium-derived contracting factors.

699 **Extracellular matrix (ECM):** the space outside the cell composed of a complex meshwork of
700 different proteins, proteoglycans, glycoproteins, polysaccharides and other structural proteins.

701 **Glycosaminoglycans:** large linear polysaccharides containing repeating disaccharide units with
702 an amino sugar (either GlcNAc or GalNAc) and an uronic acid. Five identified glycosaminoglycan
703 chains exist: hyaluronan, dermatan, keratin, chondroitin and keratan.

704 **Homeostatic model assessment of insulin resistance (HOMA-IR):** method to assess insulin
705 resistance and β -cell function, from basal (fasting) glucose and insulin or C-peptide concentrations.

706 **Hyaluronan:** an anionic, nonsulfated glycosaminoglycan. It is a major component of the ECM
707 and has multiple functions, including creating space between cells and facilitating cell migration.

708 **Hyperinsulinemic-euglycemic clamp (insulin clamp):** the gold standard for assessing insulin
709 action *in vivo*. During the insulin clamp, insulin is infused at a constant rate and glucose is infused
710 at a variable rate to maintain euglycemia. The amount of glucose that is infused reflects the insulin
711 sensitivity. The insulin clamp can be combined with tracer techniques to determine sites of insulin
712 resistance.

713 **Interstitial space:** the narrow, fluid filled areas that surround the cells of a tissue.

714 **Myofibroblasts:** cells in a state between a fibroblast and a smooth muscle cell. Fibrogenic cells
715 are not part of the normal tissue and are only present following cellular injury. Often characterized
716 by the presence of ruffled membranes and a highly active endoplasmic reticulum.

717 **Nonalcoholic fatty liver disease (NAFLD):** also known as fatty liver disease, refers to the
718 accumulation of excess lipids in liver cells that can induce inflammation and fibrosis.

719 **Oxidative stress:** the imbalance between the production of reactive oxygen species (ROS) and
720 antioxidant defenses that may result in tissue damage.

721 **Relaxin:** a protein hormone that acts through two G-protein coupled receptors RXFP1 and RXFP2
722 and has effects on the cardiovascular system. The vascular effects of relaxin include vasodilation
723 and a decrease in systemic vascular resistance.

724 **Space of Disse:** The sinusoidal endothelium is separated from hepatocytes by the space of Disse
725 where all metabolites from the bloodstream must pass through to reach the hepatocytes. The
726 surface area of hepatocytes exposed to the space of Disse is greatly enhanced by the presence of
727 microvilli. Under normal conditions, the space of Disse is filled with loosely assembled, low-
728 density extracellular matrix (ECM) proteins.

729 **Stellate cells:** previously known as Ito cells, are quiescent vitamin A rich cells. Following liver
730 injury, they transform into activated proliferative and fibrogenic myofibroblasts. This process is
731 initiated by autocrine and paracrine stimuli including inflammatory cytokines and growth factors.

732

733

734

Figure 1
[Click here to download Figure: Figure 1.tif](#)




Figure 2

[Click here to download Figure: Figure 2.tif](#)




Figure 3
[Click here to download Figure: Figure 3.tif](#)

Diet-induced muscle insulin resistance





Figure 4
[Click here to download Figure: Figure 4.tif](#)

Diet-induced hepatic insulin resistance



[Click here to download Original Figure File: TEM figures_final.pptx](#)